TITLE

Savella

PUB. DATE
May 2009
SOURCE
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the Food and Drug Administration (FDA) for Savella of Forest Laboratories Inc. and Cypress Bioscience Inc. in the U.S. The FDA has approved the selective serotonin and norepinephrine dual reuptake inhibitor for the treatment of patients with fibromyalgia. Based on the clinical trial, Savella demonstrated significant improvements of pain, patient global assessment and physical function.
ACCESSION #
39258120

 

Related Articles

  • Forest/Cypress: Savella approval should help silence fibromyalgia critics.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p17 

    The article reports on the approval of Forest Laboratories Inc. and Cypress Bioscience Inc's Savella for the management of fibromyalgia by the U.S. Food & Drug Administration (FDA). The decision came after Savella, which is a selective serotonin and norepinephrine dual reuptake inhibitor (SNRI),...

  • Pipeline.  // Medical Marketing & Media;Feb2009, Vol. 44 Issue 2, p10 

    The article offers news briefs relative to the pharmaceutical industry in the U.S. The Food and Drug Administration's (FDA) approval for Savella, a dual reuptake inhibitor for fibromyalgia containing a selective serotonin and norepinephrine, is reported to have finally been given to Forest...

  • Reviewers Give Thumbs Down for Forest CHF Drug.  // BioWorld Today;1/8/2010, Vol. 21 Issue 5, p3 

    The article reports that drug reviewers has rejected the new drug application of Bystolic (nebivolol), an oral beta-selective, beta-adrenergic blocking agent with vasodilating activity from Forest Laboratories Inc. The reviewers recommended against the approval of the drug because the results...

  • Forest/Cypress: Savella approval should help silence fibromyalgia critics.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p14 

    The article reports on the announcement of Forest Laboratories Inc. and Cypress Bioscience Inc. that the U.S. Food & Drug Administration (FDA) has approved Savella for the management of fibromyalgia. It states that Savella marks the third FDA approved treatment for the syndrome. It notes that...

  • Forest Laboratories Inc. and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article focuses on a clinical study related to the testing of levomilnacipran, an investigational agent for the treatment of major depressive disorder (MDD) in adults, which revealed the significance of this drug in reducing depression symptoms in patients with MDD. Marco Taglietti,...

  • Fibromyalgia Competition Heats Up with FDA Approval of Savella. Hollingsworth, Catherine // BioWorld Today;1/16/2009, Vol. 20 Issue 10, p4 

    The article reports on the approval of Savella by the U.S. Food and Drug Administration (FDA) for fibromyalgia. Savella marketers Forest Laboratories Inc. and Cypress Bioscience Inc. claim their product is different from current drugs that treat fibromyalgia as Savella addresses pain, physical...

  • Forest Laboratories and Cypress to launch fibromyalgia drug.  // PharmaWatch: CNS;Apr2009, Vol. 8 Issue 4, p15 

    The article reports on the announcement of the pharmaceutical companies Forest Laboratories Inc. and Cypress Bioscience Inc. to ship Savella to wholesalers and pharmacies by the middle of 2009. It states that Savella, a selective serotonin and norepinephrine reuptake inhibitor, was approved by...

  • Forest Gets PADAC Vote, but No Gold Stars for COPD Drug. Serebrov, Mari // BioWorld Today;2/24/2012, Vol. 23 Issue 37, p1 

    The article reports on the positive support received by Forest Laboratories Inc. from the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee (PADAC) for the approval of its inhaled aclidinium bromide. The drug is indicated for treating bronchospasms associated with...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p37 

    The article offers news briefs relating to the ophthalmic business industry as of February 25, 2014. The European Medicines agency released marketing authorization for the preservative-free, single-dose formulation of Ganfort. Health Canada has approved the drug Jetrea for treating symptomatic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics